Corneal astigmatism patients achieve spectacle independence with toric IOL

Article

Implantation of toric multifocal IOL in patients with cataract and corneal astigmatism provides good distance and near visual outcomes and spectacle independence.

Implantation of toric multifocal IOL in patients with cataract and corneal astigmatism provides good distance and near visual outcomes and spectacle independence, according to research featured in the Journal of Cataract and Refractive Surgery.

An investigation led by Dr Nienke Visser, University Eye Clinic Maastricht, The Netherlands, looked at 45 eyes of 25 patients with cataract, corneal astigmatism and a motivation for spectacle independence. Each patient underwent cataract surgery and implantation of a toric diffractive multifocal IOL (AT Lisa).

At three months postoperatively uncorrected distance visual acuity (UDVA), uncorrected intermediate visual acuity (UIVA) and uncorrected near visual acuity (UNVA) were measured. In addition to this the researchers looked at corrected distance, intermediate and near visual acuities, residual refractive astigmatism, defocus curve, contrast sensitivity and patient satisfaction.

The findings demonstrated high contrast sensitivity and a spectacle independence for distance and near vision in 95% of patients and 79% patients, respectively. The study produced a postoperative mean of was 0.04 logMAR ± 0.15 (SD). Of the eyes studied, 98% presented with a UDVA of 20/40 or better. Mean UNVA was recorded at 0.20 ± 0.16 logMAR and mean UIVA was 0.40 ± 0.16 logMAR.

In 90% of the eyes featured in the study a residual refractive astigmatism of −1.00 D or less was achieved. Moderate glare, halos and starburst symptoms were present in approximately 50% of patients.

Toric IOL implantation enables patients with significant levels of corneal astigmatism to achieve distance and near spectacle independence.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.